- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00726973
Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
A Pilot Study With Reduced Fluence Photodynamic Therapy With Visudyne Ranibizumab VS. Ranibizumab Only to Treat Exudative AMD
The purposes of this study is to determine if combination reduced fluence photodynamic therapy and Ranibizumab has:
Similar efficacy to Ranibizumab (Lucentis) alone. The ability to reduce the number of intravitreal injection of Ranibizumab or a 13 month period The ability to reduce the number of PDT treatments. The study will also collect information on the safety of combination therapy and single therapy.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This will be a 13 month prospective, blinded, randomized sham controled parallel safety study. There will be 2 treatment arms.
Arm 1 will receive reduced fluence PDT at baseline followed immediately by an intravitreal injection of Lucentis. Subjects in arm 1 will receive 2 additional injections of Ranibizumab (Lucentis) over the next 2 months. Starting at month 3, they will receive combination reduced fluence PDT and intravitreal Ranibizumab (Lucentis) if they develop recurrence of the subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness > 100 microns compared to the best prior thickness measure on OCT. Patients will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab (Lucentis) every 3 months thereafter. Group 1 patients are eligible for treatment with combination reduced fluence PDT and Ranibizumab (Lucentis) at any point at the 3 month time point or thereafter. After month 3, if patients were not eligible for combined therapy (<3 months since the last combination therapy) and have >2 lines of vision loss or > 100 microns of increased retinal thickness on OCT compared to most recent measure at their monthly visit, they would be eligible for an injection of Ranibizumab (Lucentis) as monotherapy. Thereafter, subjects will have combination therapy if retreatment criteria were met and it has been >3 months since the last PDT treatment.
Study arm 2 will receive 3 monthly intravitreal injections of Ranibizumab (Lucentis). Following month 2, they will be eligible for re-treatment with Ranibizumab (Lucentis) if retreatment criteria are met (same criteria as study arm 1). At intervals of no less than 3 months from the previous sham PDT, they will receive sham PDT if retreatment criteria are met.
Tipo di studio
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male / Female > 50 years of age
- FA diagnosis of CNV lesions as described above
- Have a best corrected visual acuity letter score in the study eye between 72-24 letters (approximately 20/40 to 20/320) using ETDRS chart measured at 4 meters
- Central retinal (including lesion) thickness greater than or equal to 250 microns as measured by OCT
- Subretinal hemorrhage making up less than 50% of total lesion size and sparing the fovea
- Sufficiently clear ocular media including the lens to allow photography of the retina
- Written informed consent has been obtained.
Exclusion Criteria:
- Dense subfoveal hemorrhage (>50% of the lesion)
- Tear or rip of the retina pigment epithelium, idiopathic parafoveal telangiectasis or serous pigment epithelial detachment without CNV
- Geographic atrophy involving the foveal center
- Subretinal fibrotic scar in the study eye greater than 25% of the lesion
- Presence of any condition in study eye other than AMD known to be associated with CNV
- History diabetic retinopathy or diabetic macular edema
- Previous pars plana vitrectomy
- Previous photodynamic therapy in the study eye
- Previous photodynamic therapy in the fellow eye with resultant choroidal hypoperfusion
- Previous intravitreal anti-VEGF or steroid injection in the study eye
- Previous thermal subfoveal laser treatment in study eye
- Anticipated need for ocular surgery in the study eye during the 13 month study period
- Known allergy or sensitivity to the study medication(s) its components, diagnostic agents used during the study (Fluorescein, dilation drops) or other agents required for the study procedures (ie: povidone iodine)
- Porphyria or other porphyrin sensitivity
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: 1
Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
|
Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab.
For 2 months injected intravitreal Ranibizumab will be given.
At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab.
If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
Altri nomi:
|
Comparatore attivo: 2
Ranibizumab monotherapy
|
3 monthly intravitreal injections of Ranibizumab monotherapy.
After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Primary efficacy will be proportion of subjects with best corrected visual acuity improvement of 15 or more letters from baseline and wil visual acuity stabilization, less than 15 letter loss from baseline at 13 months
Lasso di tempo: at conclusion of subject enrollment
|
at conclusion of subject enrollment
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Mean change in ETDRS from baseline, number of Ranibizumab treatments w/reduced fluence PDT, proportion of patients with 6 lines of vision loss
Lasso di tempo: at conclusion of subject enrollment
|
at conclusion of subject enrollment
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jeffrey L Marx, M.D., Lahey Clinic Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2006-085
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Edema maculare
-
Federico II UniversityCompletatoEdema maculare cistoide pseudofachico
-
Eye-yon MedicalCompletatoEDEMA CORNEALEIsraele, Polonia
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletatoEdema maculare diabetico | Edema maculare cistoideStati Uniti
-
Postgraduate Institute of Medical Education and...CompletatoEdema maculare diabetico | Disturbi della vista | Edema maculare, cistoide | Edema maculare clinicamente significativoIndia
-
OcugenNon ancora reclutamentoEdema maculare diabetico | Centro coinvolto Edema maculare diabetico
-
National Cardiovascular Center Harapan Kita Hospital...CompletatoEdema miocardico
-
OculisICON plcReclutamentoEdema maculare diabeticoStati Uniti
-
Novartis PharmaceuticalsNon ancora reclutamento
-
Hoffmann-La RocheReclutamentoEdema maculare uveiticoCorea, Repubblica di, Regno Unito, Cina, Stati Uniti, Olanda, Canada, Israele, Austria, Brasile, Italia, Taiwan, Polonia, Portogallo, Messico
Prove cliniche su Ranibizumab
-
University of Campania "Luigi Vanvitelli"Completato
-
University of Illinois at ChicagoGenentech, Inc.RitiratoGlaucoma | Glaucoma neovascolare | Glaucoma di nuova insorgenza | Glaucoma neovascolare di nuova insorgenza
-
Lupin Ltd.ReclutamentoDegenerazione maculare legata all'età neovascolareIndia
-
New England Retina AssociatesGenentech, Inc.CompletatoMelanoma coroidaleStati Uniti
-
Hawaii Pacific HealthGenentech, Inc.CompletatoVasculopatia coroidale polipoidale | PCVStati Uniti
-
Samsung Bioepis Co., Ltd.CompletatoDegenerazione maculare legata all'etàCorea, Repubblica di, Stati Uniti, India, Germania, Ungheria, Regno Unito, Cechia, Polonia, Federazione Russa
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletatoEdema maculare diabeticoArgentina, Messico
-
Instituto de Olhos de GoianiaCompletato
-
Pusan National University HospitalNovartisCompletatoDegenerazione maculare essudativa senileCorea, Repubblica di
-
Vista KlinikCompletatoDegenerazione maculare legata all'età | Neovascolarizzazione coroidaleSvizzera